Process to receive WHO pre-qualification for Covaxin on, says govt

Covishield manufactured by the Serum Institute of India (SII) has received the WHO pre-qualification, while the process of pre-qualification for Bharat Biotech's Covaxin is going on

Process to receive WHO pre-qualification for Covaxin on, says govt
Press Trust of India New Delhi
2 min read Last Updated : Jul 20 2021 | 10:58 PM IST

Of the two vaccines presently being procured for the ongoing COVID-19 vaccination, Covishield manufactured by the Serum Institute of India (SII) has received the WHO pre-qualification, while the process of pre-qualification for Bharat Biotech's Covaxin is going on, the government informed Parliament on Tuesday.

In a written reply to a question in the Rajya Sabha, Minister of State for Health Bharati Pravin Pawar said the application for pre-qualification is submitted by the manufacturer directly to the World Health Organization (WHO).

In response to a question on when the WHO approval for Covaxin is expected, the minister said the data required for approval was submitted by Bharat Biotech International Limited to WHO on July 9.

"Based on the time taken for approval of other COVID-19 vaccines, it is estimated that the WHO-EUL process takes approximately two to three months from the date of submission," she said.

On the steps that the government is taking or has taken to ensure that more WHO-approved vaccines are made available in the country, Pawar said the regulatory norms have been streamlined for the approval of import and usage of the offshore-manufactured vaccines in India that have received the Emergency Use License (EUL) by the FDA of the United States, the MHRA of the United Kingdom, the PMDA of Japan or the WHO-EUL.

The minister further informed that the Covid vaccine manufactured by Moderna has already been approved for import and usage in the country by the Drugs Controller general of India (DCGI).

The National Empowered Group on Vaccine Administration against COVID-19 (NEGVAC) is in regular talks with offshore manufacturers for facilitating the import of Covid vaccines, some of which have already received the WHO pre-qualification, she added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Bharat BiotechCoronavirus VaccineWHO

First Published: Jul 20 2021 | 10:58 PM IST

Next Story